Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Bucknelly21on Jun 14, 2021 7:43pm
137 Views
Post# 33386087

RE:RE:RE:RE:RE:RE:RE:RE:Schwab

RE:RE:RE:RE:RE:RE:RE:RE:Schwab
scarlet1967 wrote: They had many milestones, a small company managed to put two protocols together and get the go ahead from FDA and likely EMA for NASH soon, they managed to sell their drugs at pre pandemic levels through out pandemic when health care systems mostly were/are dealing with the COVID patients. I recall some didn't see the announcement of IND as material event but approved INDs would be the real deal, on the absence of any reaction from the market some now moving on to Hard data well it's not a rocket science if data are great then the SP will appreciate. But it wil appreciate from a very low level!!
The company has to reach out to broader audience and put themselves in their position, what is it the investors want to hear to invest?
Just explanation of the science doesn't answer an investor's question whether they would invest their hard earned money,but to make it clear that each piece of new positive findings each achieved milestone etc will bring this company closer to $$ billions of revenues will create a desire to get invested in a company with descent scientific prospects which if successful can create a very profitable business. Yes we will be making billions if one or and both programs are successful, yes at this prices you can miss a huge opportunity not to have THTX in your portfolio, yes it is high risk high return but since there is a valuation discrepancies between THTX and the comps the risk reward ratios are extremely favourable compared to comps. Investors  needs to understand what will be happening when one or both programs end up being successful and they need to hear it from the company itself. The company needs to understand THTX is not a charitable not profitable organization but a public company listed on NASDAQ with real investors who expect returns crowded by competitors in their industry.
Get the plan going and don't be shy trying different strategies. We are in a bull market although the NBI is data driven in case there is a correction it will be some negative spill over effects on high risk high return companies with thin balance sheets so build up some buffer in the valuation for that eventuality now. We don't want to end up with too little too late scenario.
Bucknelly21 wrote:
Wino115 wrote:

Any milestones that bring the magnitude of likely revenues into sight will create the step function upward we've seen in other biotechs.  We just need a moderate sized audience that gets it and hopefully the IR plan creates it.  Milestones will help that too.

 

qwerty22 wrote:

 

Milestones

 

palinc2000 wrote: I think you are giving too much weight LSA  s impact ,,,The best promoter for the stock is THTX and its CEO,,,LSA does not have a magic wand ,,,,Hopefully they will add strength to an upswing in the stock price but  something is needed to ignite the fire and thats management s job

 

 


 
we seem to need a lot from Thtx......
 


my biggest fear with this whole thing 

<< Previous
Bullboard Posts
Next >>